Meeting
2021 ASCO Annual Meeting
A phase I dose-escalation study to evaluate pharmacokinetics, safety and tolerability of ACT001 in patients with advanced glioma.
Authors
Yehui Shi
Tianjin Medical University Cancer Hospital, Tianjin, China
Yehui Shi , Guiying Bai , Peng Wang , Dongpo Cai , Yue Chen , Ping Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
ChiCTR-OIC-17013604
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2044)
DOI
10.1200/JCO.2021.39.15_suppl.2044
Abstract #
2044
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2022 ASCO Annual Meeting
Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3‑activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.
First Author: Apostolia Maria Tsimberidou
Poster
2022 ASCO Annual Meeting
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
First Author: Miguel Angel Villalona-Calero
Poster
2022 ASCO Annual Meeting
A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.
First Author: Ursula A. Matulonis